{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"60.76","value":"-6.8"},{"groupId":"OG001","spread":"70.41","value":"2.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"description":"If airway or lower extremity motor dysfunction is evident, endurance will be measured by completion of a 6-minute walking test.","dispersionType":"Standard Deviation","groups":[{"description":"Patients aged 2 to 17 years old at the time of informed consent. Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\\^2 (maximum dose of 4 mg) by mouth twice daily","id":"OG000","title":"Treatment Phase - Pediatric Cohort Mirdametinib (PD-0325901)"},{"description":"Patients aged 18 and above at the time of informed consent. Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\\^2 (maximum dose of 4 mg) by mouth twice daily","id":"OG001","title":"Treatment Phase - Adult Cohort Mirdametinib (PD-0325901)"}],"paramType":"MEAN","populationDescription":"The Full Analysis Set patients eligible for this instrument at baseline","reportingStatus":"POSTED","timeFrame":"Baseline and Cycle 13 (1 cycle = 28 days), up to 12 months","title":"Change From Baseline in Endurance at Cycle 13.","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"meters"}